Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD2423 · 7 trials · 7 indications
Monocyte count in BAL post-LPS challenge (Day 11)
Last Observation Carried Forward (LOCF). Twice daily, the participants rated their Average Pain intensity during the past 12 hours on an Numerical Rating Scale (NRS) scale 0-10. 0= No pain, 10= Worst pain imaginable.
Number of all participants with clinically significant changes in laboratory variables, except monocyte, assessed at all the listed time points
Number of participants with clinically significant changes in vital signs assessed at all the listed time points
Number of participants with clinically significant changes in ECG variables assessed at all the listed time points
Number of participants with clinically significant changes in physical examination assessed at all the listed time points
Monocyte count in peripheral blood at baseline (Pre-dose, Day 1)
Monocyte count in peripheral blood at end of treatment (4 weeks)
Monocyte count in peripheral blood at follow-up (Week 5; 1 week after end of treatment)
Changes from baseline in systolic blood pressure, pulse rate and body temperature
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Oral treatment |
| 2 | PLACEBO_COMPARATOR | Oral treatment |
| AZD2423, 20mg | EXPERIMENTAL | - |
| AZD2423, 150 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | Tablet to match the 20 mg and 50 mg AZD2423 active tablet |
| AZD2423 | EXPERIMENTAL | AZD2423 Oral Treatment for 28 days |
| AZD2423, 20 mg | EXPERIMENTAL | Tablets, 20 mg once daily in the morning. |
| 1. AZD2423 | EXPERIMENTAL | - |
| 2. Placebo | PLACEBO_COMPARATOR | - |
| A | EXPERIMENTAL | AZD2423 |
| B | EXPERIMENTAL | Placebo |
| Name | Type | Description |
|---|---|---|
| AZD2423 | DRUG | 100mg Oral dose od |
| AZD2423 Placebo | DRUG | Oral dose od |
| Placebo | DRUG | Placebo |
| Placebo to AZD2423 | DRUG | Oral treatment once daily for 28 days |
Inclusion Criteria: * Only women of non-child bearing potential are included in the study i.e. women who are permanently or surgically sterilised or post menopausal. * ≥ 40 years of age at Visit 1 * Clinical diagnosis of COPD (GOLD stage 1) * FEV1 ≥ 80% of the predicted normal post-bronchodilator a...
AZD2423 is an investigational small molecule being studied for chronic obstructive pulmonary disease (COPD) and neuropathic pain. Clinical trials have evaluated it in healthy volunteers and in patients with mild, moderate, and severe COPD. It is not approved and remains in clinical development.
AZD2423 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the NASDAQ under the ticker symbol AZN. The company has sponsored clinical trials of AZD2423 in healthy volunteers and in patients with chronic obstructive pulmonary disease.
AZD2423 has completed Phase 1 and Phase 2 clinical trials. Phase 1 studies assessed safety and tolerability in healthy volunteers, while Phase 2 studies evaluated its effects in patients with chronic obstructive pulmonary disease. All trials are completed, and the drug remains investigational.
AZD2423 has been studied in four completed clinical trials. NCT00970775 and NCT01233830 were Phase 1 studies in healthy Japanese volunteers. NCT01153321 and NCT01215279 were Phase 2 studies in patients with chronic obstructive pulmonary disease. All trials are completed.
AZD2423 is the code name used by AstraZeneca for this investigational compound. No alternative brand or generic names have been disclosed in the clinical trial records. It is identified solely by the code AZD2423 in all registered studies.